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Introduction {#sec004}
============

The age-standardized prevalence of knee osteoarthritis (OA) is 3.8%, making OA one of the leading causes of global disability \[[@pone.0145776.ref001]\]. Intra-articular (IA) injection of hyaluronic acid (HA) has been recommended to alleviate pain and improve joint function in patients with knee OA \[[@pone.0145776.ref002]\]. Chondroprotective and analgesic properties inherent to HA \[[@pone.0145776.ref003]\] suggest that HA can delay total knee replacement (TKR) surgery \[[@pone.0145776.ref004]\], a treatment popular enough that it has become a key driver of health care costs \[[@pone.0145776.ref005]\]. It is estimated that 54% of knee OA patients will receive TKR over their lifetime under current guidelines; the current trend of expanding indications for TKR suggests that there may be a 29% increase in lifetime direct medical costs attributable to TKR among knee OA patients \[[@pone.0145776.ref006]\].

Recent OA treatment guidelines from Europe recommend that HA be used for symptom relief prior to TKR \[[@pone.0145776.ref007]\], whereas the American Academy of Orthopedic Surgeons (AAOS) recently recommended against using HA \[[@pone.0145776.ref008]\]. Considering a standardized patient with moderate knee pain and functional limitations, orthopedic surgeons and rheumatologists differ significantly in their recommendations for TKR \[[@pone.0145776.ref009]\] underscoring the need for further evidence to formulate rational OA treatment algorithms. Published clinical studies generally evaluate the efficacy of HA in reducing pain, with observation periods that rarely exceed 6 months. Yet the proposed mode of action of HA warrants investigation of its potential role in delaying the progression of disease over longer periods of time \[[@pone.0145776.ref010]\].

There are currently no completed, ongoing, or recruiting randomized clinical trials (RCTs) designed to determine whether HA can delay or prevent TKR \[[@pone.0145776.ref011]\]. The Agency for Healthcare Research and Quality (AHRQ) recently reviewed the published literature on HA injections with the aim of identifying any role in delaying TKR surgery. Given the absence of relevant RCTs, the AHRQ advocated analyzing data from a real-world administrative claims database to test whether HA use can delay TKR \[[@pone.0145776.ref011]\].

To evaluate the impact of HA use on TKR, we evaluated every patient with knee OA who received TKR in a database of approximately 79 million patients. Our hypothesis was that HA injection is associated with delay of TKR in a dose-dependent manner, such that more courses of HA will delay TKR for a longer period of time. The primary outcome was a comparison of time-to-TKR in patients who received HA, relative to patients who did not receive HA. The secondary outcome was to examine the relationship between number of HA injections and time-to-TKR.

Methods {#sec005}
=======

This retrospective claims analysis used the IMS Health PharMetrics Plus database of \~79 million patients. Because all patient data were anonymized before analysis, no Institutional Review Board (IRB) approval was required. Adjudicated health claims were aggregated from many sources; patients in each 3-digit zip code and in every Metropolitan Statistical Area of the United States are included, with coverage of data from 90% of American hospitals, 80% of American doctors, and 85% of Fortune 100 companies \[[@pone.0145776.ref012]\].

We identified all knee OA patients who received TKR within a 6-year selection window (2007--2013). We evaluated only those knee OA patients who had continuous enrollment from OA diagnosis until TKR. The initial OA diagnosis served as the index date and we evaluated time-to-TKR, in days from diagnosis, as a function of the number of courses of HA injection received, ranging from 0 to ≥5. To evaluate differences in demographic factors between HA Users and Non-users, we used χ^2^ to evaluate categorical variables and Wilcoxon rank sum for continuous variables. We also did a Cox proportional hazards analysis, to evaluate the impact of number of courses of HA injection, age (as a continuous variable), gender, and comorbidity (as a continuous variable) on the risk of TKR. Time-to-event analyses used a Kaplan-Meier survival approach. Median TKR-free survival time was defined as the time at which 50% of patients in a cohort received TKR. Log-rank tests were used to compare TKR-free survival times for the different HA cohorts. All statistical analyses were performed using SAS 9.2 (SAS Institute; Cary, NC).

Results {#sec006}
=======

The database of \~79 million patients yielded 328,306 patients who had TKR between July, 2007 and June, 2013 ([Fig 1](#pone.0145776.g001){ref-type="fig"}). After excluding patients lacking an OA diagnosis, lacking continuous enrollment, lacking drug records, or having various exclusionary diagnoses (lupus erythematosus, gout, rheumatoid arthritis, fibromyalgia, hip OA), the database included 182,022 patients with both knee OA and TKR who met all inclusion criteria. Roughly 55% of possible TKR patients (= 182,022/328,306) are included in the present analysis ([Fig 1](#pone.0145776.g001){ref-type="fig"}).

![PRISMA-style diagram.\
This Fig summarizes how patients were accrued to the study.](pone.0145776.g001){#pone.0145776.g001}

A total of 50,349 (27.7%) patients were classified as HA Users, receiving 1 or more courses of HA, while 131,673 patients (72.3%) were classified as HA Non-users ([Table 1](#pone.0145776.t001){ref-type="table"}). Age, gender, and Charlson Comorbidity Index (CCI) scores differed significantly between patients who did and did not use HA ([Table 1](#pone.0145776.t001){ref-type="table"}), though sample sizes in this database are so large that differences that are not clinically important can still be statistically significant. Patients who received a TKR without first using HA were on average 1.8 years older than patients who used HA prior to TKR, with HA Non-users involving fewer patients in the age 45 to 54 stratum and more patients in the age \>65 stratum. HA Non-users were also more likely to be men, less likely to be self-insured, and more likely to consult an orthopedic surgeon ([Table 1](#pone.0145776.t001){ref-type="table"}).

10.1371/journal.pone.0145776.t001

###### Demographic descriptors of HA Users and HA Non-users.

The P value shown is for a χ^2^ evaluation of all demographic descriptors in the category. The heading "GP/FP/IM" includes physicians in General Practice, Family Practice, and Internal Medicine.
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                                          HA Patients   Non-HA Group                    
  --------------------------------------- ------------- -------------- -------- ------- ----------
  **Age (n,%):**                                                                        
    18--44 years                          1,713         3.4%           2,966    2.3%    \< .0001
    45--54                                12,193        24.2%          23,563   17.9%   
    55--64                                24,034        47.7%          63,540   48.3%   
    65+                                   12,409        24.6%          41,604   31.6%   
    Mean                                  59.7                         61.5             \< .0001
    SD                                    8.9                          8.9              
  **Gender (n,%):**                                                                     
    Male                                  19,386        38.5%          57,628   43.8%   \< .0001
  **Payer Type (n,%):**                                                                 
    Commercial Plan                       29,770        59.1%          79,036   60.0%   \< .0001
    Medicaid                              241           0.5%           884      0.7%    
    Medicare Risk                         1,759         3.5%           6,348    4.8%    
    Medicare Cost                         934           1.9%           2,973    2.3%    
    Self-Insured                          17,328        34.4%          41,708   31.7%   
    Unknown                               317           0.6%           724      0.5%    
  **Physician Specialty (n,%):**                                                        
    Orthopedic Surgery                    22,051        43.8%          59,547   45.2%   \< .0001
    GP/FP/IM                              5,212         10.4%          13,436   10.2%   
    Orthopedics                           3,486         6.9%           9,376    7.1%    
    Rehab. Medicine                       950           1.9%           1,416    1.1%    
    Rheumatology                          722           1.4%           838      0.6%    
    Other                                 17,928        35.6%          47,060   35.7%   
  **Charlson Comorbidity Index (n,%):**                                                 
  0                                       32,992        65.5%          84,797   64.4%   \< .0001
  1                                       9,036         17.9%          23,943   18.2%   
  2                                       5,134         10.2%          13,789   10.5%   
  3                                       1,837         3.6%           5,189    3.9%    
  4+                                      1,350         2.7%           3,955    3.0%    
    **Mean CCI**                          0.6                          0.7              \< .0001
    SD                                    1.1                          1.1              
    Median                                0                            0                

A Cox proportional hazards model shows that the risk of having TKR decreases as a function of the number of courses of HA injection, if patient age (as a continuous variable), patient gender, and patient comorbidity (as a continuous variable) are added as background covariates ([Table 2](#pone.0145776.t002){ref-type="table"}). Our analysis shows that \"HA 1 course vs non HA cohort\" significantly delays TKR (P \< 0.0001) after controlling for age, gender, and CCI. The hazard ratios for number of HA courses are all statistically significant and less than one, suggesting that HA injection is protective from the risk of TKR (all, P \< 0.0001). The hazard ratios for age and gender are also statistically significant, but do not influence risk of TKR as much as does HA injection. CCI, treated as a continuous variable, does not significantly increase the risk of TKR ([Table 2](#pone.0145776.t002){ref-type="table"}). These findings suggest that, while there are clinical differences between HA users and HA non-users in background covariates, an important difference is in HA use itself.

10.1371/journal.pone.0145776.t002

###### Risk of TKR as a function of number of courses of HA injection, age, gender, and comorbidity.

Coeff. is the coefficient of a Cox proportional hazards model; a negative value indicates that the variable is protective from the risk of TKR. Comorbidity is expressed as the Charlson Comorbidity Index (CCI). The P value shown is for a χ^2^ evaluation of each independent variable.
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                                            Standard   Hazard   95% CI           
  -------------------------------- -------- ---------- -------- -------- ------- ----------
  HA 1 course v. non-HA cohort     -0.571   0.006      0.565    0.559    0.572   \< .0001
  HA 2 courses v. non-HA cohort    -0.901   0.011      0.406    0.397    0.415   \< .0001
  HA 3 courses v. non-HA cohort    -1.132   0.019      0.322    0.310    0.335   \< .0001
  HA 4 courses v. non-HA cohort    -1.265   0.031      0.282    0.266    0.300   \< .0001
  HA ≥5 courses v. non-HA cohort   -1.496   0.036      0.224    0.209    0.241   \< .0001
  Age (continuous variable)        0.010    0.000      1.010    1.009    1.010   \< .0001
  Gender: male vs. female          0.042    0.005      1.043    1.033    1.053   \< .0001
  CCI (continuous variable)        -0.002   0.002      0.998    0.994    1.003   0.4328

Among HA Users, 73.2% received 1 course of HA treatment, 17.7% received 2 courses, 5.5% received 3 courses, 2.1% received 4 courses, and 1.5% received ≥5 courses ([Table 3](#pone.0145776.t003){ref-type="table"}). Median time-to-TKR increased from 114 days for patients with no use of HA to 484 days for patients who received any HA injection ([Table 3](#pone.0145776.t003){ref-type="table"}). Time from OA diagnosis to when 50% of patients received TKR was significantly (p\<0.0001) and substantially longer for HA Users, compared to HA Non-users. Half of HA Non-users had a TKR at 114 days post-diagnosis, whereas half of HA Users had a TKR at 484 days post-diagnosis (χ^2^ = 19,769; p \< 0.0001), more than 4 times longer than the median time-to-TKR of HA Non-users ([Table 3](#pone.0145776.t003){ref-type="table"}).

10.1371/journal.pone.0145776.t003

###### Timing of total knee replacement (TKR) for all patients.

Patients in the HA cohort got a TKR on average 601.8 days after OA diagnosis, which is significantly longer than the mean time-to-TKR of 270.3 days in patients who did not receive HA (χ^2^ = 19,769.1; p \< 0.0001).
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                                      Sample   Median   Mean      SD                    
  ------------------- --------------- -------- -------- --------- ---------- ---------- ----------
  **Non-HA cohort**   131,673         114      270.3    355.5     \-         \-         
  **HA cohort**       50,349          484      601.8    433.2     19,769.1   \<0.0001   
                      1 HA course     36,861   386      513.7     400.1      13,724.6   \<0.0001
                      2 HA courses    8,893    648      741.7     408.6      18,138.7   \<0.0001
                      3 HA courses    2,783    875      945.6     390.5      19,363.5   \<0.0001
                      4 HA courses    1,052    1,054    1,085.1   356.1      19,664.4   \<0.0001
                      ≥5 HA courses   760      1,312    1,306.0   355.7      19,934.6   \<0.0001

Disease comorbidities and medication use at or before OA diagnosis were similar between HA Users and HA Non-users ([Table 4](#pone.0145776.t004){ref-type="table"}). Several illnesses were somewhat more prevalent among HA Users, including hyperlipidemia, major depression, bipolar disorder, liver disease, and substance abuse disorder, while schizophrenia and anemia were equally prevalent between HA Users and HA Non-users. HA Non-users were somewhat more likely to have hypertension, diabetes, vascular disease, renal disease, and chronic obstructive pulmonary disease. HA Users used somewhat more of all medications at or before OA diagnosis, including corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and proton-pump inhibitors.

10.1371/journal.pone.0145776.t004

###### Summary of comorbidities and medications among HA Users and HA Non-users.
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                                            HA Users   HA Non-Users            
  ----------------------------------------- ---------- -------------- -------- -------
  **Comorbidities of Interest (n,%):**                                         
    Hypertension                            22,991     45.7%          61,494   46.7%
    Hyperlipidemia                          21,236     42.2%          53,197   40.4%
    Diabetes                                8,251      16.4%          23,443   17.8%
    Schizophrenia                           54         0.1%           105      0.1%
    Major depression                        1,534      3.0%           3,171    2.4%
    Bipolar disorder                        473        0.9%           984      0.7%
    Vascular disease                        12,479     24.8%          33,568   25.5%
    Liver disease                           1,238      2.5%           2,764    2.1%
    Renal disease                           2,563      5.1%           7,092    5.4%
    Substance abuse disorder                1,569      3.1%           3,921    3.0%
    Chronic obstructive pulmonary disease   1,687      3.4%           4,707    3.6%
    Anemia                                  3,254      6.5%           8,572    6.5%
  **Medications of Interest (n,%):**                                           
    Corticosteroids                         14,296     28.4%          27,407   20.8%
    NSAIDs                                  14,112     28.0%          29,953   22.7%
    COX-2 inhibitors                        3,149      6.3%           6,977    5.3%
    Analgesics non-narcotic                 619        1.2%           1,229    0.9%
    Opioids                                 17,763     35.3%          40,980   31.1%
    Non-NSAID analgesics                    149        0.3%           290      0.2%
    H^2^ blockers                           1,056      2.1%           2,521    1.9%
    Proton pump inhibitors                  9,271      18.4%          20,876   15.9%

More courses of HA injection were associated with a longer time-to-TKR in a dose-dependent manner ([Fig 2](#pone.0145776.g002){ref-type="fig"}). Patients who received no HA had a mean time-to-TKR of about 0.7 years (median = 0.3 years). With only one course of HA, the mean time to TKR was 1.4 years (χ^2^ = 13,725; p \< 0.0001) (median = 1.1 years), while patients who received ≥5 courses delayed TKR by a mean of 3.6 years (χ^2^ = 19,935; p \< 0.0001) (median = 3.6 years). Roughly 22.2% of patients with ≥5 HA courses were able to delay TKR by 4.5 years or more. All HA User cohorts were significantly (p \< 0.0001) and substantially different from HA Non-users in time-to-TKR.

![Time-to-TKR as a function of number of courses of HA injection.\
Each individual comparison of an HA User cohort to HA Non-users was significant (p \< 0.0001; see [Table 3](#pone.0145776.t003){ref-type="table"}). All HA cohorts had substantially longer time-to-TKR than HA Non-users (all, p \< 0.0001), with the weakest significance for patients who got only 1 course of HA injection (χ^2^ = 13,724.6; p \< 0.0001).](pone.0145776.g002){#pone.0145776.g002}

Discussion {#sec007}
==========

Among 182,022 patients with knee OA, those who received HA injections showed a significantly longer time-to-TKR (p \< 0.0001). More courses of HA treatment were associated with a longer time-to-TKR, in a dose-dependent manner, consistent with our initial hypothesis. Patients who received no HA had a median time-to-TKR of \~0.3 years; with only one course of HA, the median time to TKR was \>1.0 year (χ^2^ = 13,725; p \< 0.0001); patients who received ≥5 courses delayed TKR by 3.6 years (χ^2^ = 19,935; p \< 0.0001).

The strongest evidence suggesting that HA can delay TKR is the clear dose-response relationship between number of HA courses and time-to-TKR ([Fig 2](#pone.0145776.g002){ref-type="fig"}). While it is essentially impossible to prove a causal inference linking an event with an outcome \[[@pone.0145776.ref013]\], the dose-response relationship between HA and delay of TKR ([Fig 2](#pone.0145776.g002){ref-type="fig"}) would seem to satisfy many of Hill's criteria for causation \[[@pone.0145776.ref014]\]: the relationship between number of HA courses and time-to-TKR is statistically very strong (legend, [Fig 2](#pone.0145776.g002){ref-type="fig"}); the smoothness of the curves ([Fig 2](#pone.0145776.g002){ref-type="fig"}) suggests intra-patient consistency of treatment response; the selection criteria used ([Fig 1](#pone.0145776.g001){ref-type="fig"}) ensure that the relationship between event and outcome has both high specificity and clear temporality; greater use of HA is associated with a longer time-to-TKR ([Fig 2](#pone.0145776.g002){ref-type="fig"}); and there is a plausible mechanism linking cause and effect \[[@pone.0145776.ref010]\].

Our results are consistent with previous research showing that HA can delay TKR. Retrospective analysis of 248 knee OA patients, using TKR as the endpoint during a 6-month follow-up, concluded that HA may have delayed TKR in 80% of patients \[[@pone.0145776.ref015]\]. Similarly, TKR was avoided or significantly delayed in 15 of 19 patients who were considering surgery prior to HA injection \[[@pone.0145776.ref016]\]. In a study of patients with Grade IV OA \[[@pone.0145776.ref017], [@pone.0145776.ref018]\], a total of 1,978 courses of HA were given to 1,187 knees, at an average cost of \$1,420 per knee, to delay TKR by a median of 2.1 years \[[@pone.0145776.ref017]\]. Survival analysis of this group showed that TKR was delayed more than 7 years in 75% of HA-treated patients with Grade IV OA \[[@pone.0145776.ref018]\]. However, only 19% (N = 225) of patients in this study had TKR \[[@pone.0145776.ref017]\]. The sample size we report is therefore more than 800-fold larger and provides a higher degree of statistical confidence.

There is also recent evidence from the Truven MarketScan database that repeated courses of HA injection can delay TKR in a dose-dependent fashion by a median of 2.6 years, based on a population of 16,589 patients \[[@pone.0145776.ref004]\]. Claims analysis in the Blue Cross-Blue Shield database for New Jersey showed that mean time-to-TKR after starting HA was approximately 2.5 years, though 75% of patients underwent TKR within 1 year of starting HA \[[@pone.0145776.ref019]\]. In a Spanish study of 224 patient candidates for TKR, HA use was associated with a delay in need for surgery that averaged 2.7 years \[[@pone.0145776.ref020]\]. Clinic-based studies also suggest that repeated cycles of HA injection can delay time-to-TKR \[[@pone.0145776.ref021]\]. There is thus a growing consensus that HA injections can delay TKR by several years \[[@pone.0145776.ref022]\], and our results are consistent with that conclusion ([Table 3](#pone.0145776.t003){ref-type="table"}; [Fig 2](#pone.0145776.g002){ref-type="fig"}).

How can HA injections delay TKR by several years? Synovial fluid in the joint space is a lubricant and shock absorber \[[@pone.0145776.ref023]\], and early research suggested that injected HA restores the rheological properties of synovial fluid \[[@pone.0145776.ref024]\]. However, improved shock absorption and lubrication alone do not explain the multi-year improvement associated with HA injection; improvement also depends upon biologic effects on the cartilage and joint space, and perhaps even on pain perception \[[@pone.0145776.ref025]\]. There is evidence that HA suppresses the production and activity of pro-inflammatory molecules and degradative enzymes, and can alter immune cell function \[[@pone.0145776.ref003], [@pone.0145776.ref010], [@pone.0145776.ref024]\]. Histological evidence demonstrates that HA injections can prevent cartilage degradation and may promote cartilage regeneration \[[@pone.0145776.ref010]\]. Injected HA can also stimulate endogenous HA production and normalize the rheology of synovial fluid in the OA knee \[[@pone.0145776.ref026]\]. The physiological effects of injected HA are thus associated with a multifactorial mechanism for HA-related symptomatic improvement.

Use of HA for OA patients has become controversial despite widespread use. The Osteoarthritis Research Society International (OARSI) stated in its 2008 guidelines that IA injections of HA "may be useful in patients with knee or hip OA. \[HAs\] are characterized by delayed onset, but prolonged duration, of symptomatic benefit when compared to IA injections of corticosteroids" \[[@pone.0145776.ref002]\]. Use of HA for knee OA has been recommended by the American College of Rheumatology (ACR) \[[@pone.0145776.ref027]\], the European League Against Rheumatism (EULAR) \[[@pone.0145776.ref028]\], and the Michigan Quality Improvement Consortium (MQIC) \[[@pone.0145776.ref029]\]. However, recent guidance from OARSI concluded that the benefit of HA was "uncertain" for knee OA, though the effect size for pain relief following HA injection ranged from 0.37 to 0.46 and the overall evidence quality was "good" \[[@pone.0145776.ref030]\]. Clinical Practice Guidelines from the Veterans Affairs/Department of Defense \[[@pone.0145776.ref031]\] state that HA "may be considered for patients who have not responded adequately to non-pharmacologic measures and who have an inadequate response, intolerable adverse events, or contraindications to other pharmacologic therapies." Conversely, a systematic review by the U.S. Bone and Joint Initiative describes HA use as controversial \[[@pone.0145776.ref032]\], and both the National Collaborating Center for Chronic Conditions (NCC-CC) \[[@pone.0145776.ref033]\] and the American Academy of Orthopedic Surgeons (AAOS) \[[@pone.0145776.ref008]\] have recommended against using HA. The AAOS evaluation of evidence in particular has been faulted for misinterpreting the minimum clinically important improvement necessary to recommend HA therapy \[[@pone.0145776.ref034]\]. Finally, a recent network meta-analysis incorporating 33,243 patients concluded that HA was superior to both NSAIDs (acetaminophen, celecoxib, and naproxen) and placebo (oral and intra-articular) for knee OA pain relief \[[@pone.0145776.ref035]\].

The formulation of rational treatment algorithms for HA use should take into account whether HA injection alters disease progression \[[@pone.0145776.ref011]\]. While our results show unequivocally that HA injection is associated with a delay in time-to-TKR by 3.3 years ([Fig 2](#pone.0145776.g002){ref-type="fig"}), our results do not address whether there is a direct patient benefit from such delay. One could imagine that at least some patients who postpone TKR may ultimately avoid knee surgery completely, as suggested in a retrospective trial \[[@pone.0145776.ref018]\].

Might there be a patient benefit from avoiding TKR? Mortality rates following elective TKR have decreased substantially over the last 30 years \[[@pone.0145776.ref036]\], but TKR is still associated with serious adverse events (AEs). The incidence of several important AEs associated with TKR increased or did not change from 1999 to 2008, including pulmonary embolism, pneumonia, and cardiac complications \[[@pone.0145776.ref037], [@pone.0145776.ref038]\]. AEs affect roughly 6% of Medicare patients receiving TKR and the risk of congestive heart failure and chronic obstructive pulmonary disease roughly double during surgical hospitalization \[[@pone.0145776.ref039]\]. A recent population-based study used propensity-matching to compare TKR patients with non-TKR controls and concluded the hazard ratio for myocardial infarction was significantly elevated to 8.8 in the immediate post-operative period \[[@pone.0145776.ref040]\]. The overall surgical infection rate following TKR was 1% in 5,277 surgeries \[[@pone.0145776.ref041]\], and rates of sepsis and severe sepsis have not declined in recent years \[[@pone.0145776.ref042]\]; infection rates can be substantially higher in patients who are morbidly obese, diabetic, or younger in age \[[@pone.0145776.ref043]\]. Finally, up to 1.7% of patients who get TKR need revision surgery because of implant failure \[[@pone.0145776.ref044]\]. In a large cohort of patients, the unplanned hospital readmission rate following TKR was 4% at 30 days post-surgery and 8% at 90 days \[[@pone.0145776.ref045]\]. Among Medicare beneficiaries specifically, the 30-day hospital readmission rate was 5% in 2010 \[[@pone.0145776.ref046]\]. In aggregate, these findings suggest that some patients may not benefit from TKR, though TKR can yield substantial improvements in physical function and general health \[[@pone.0145776.ref047]\], including conferring a mild cardioprotective effect over at least 2 ensuing years \[[@pone.0145776.ref048]\]. These conclusions were recently confirmed in a randomized controlled trial that enrolled 95 patients and found that TKR resulted in greater pain relief and functional improvement after 12 months, at the cost of a rate of serious AEs roughly 4-fold higher than the group which received nonsurgical treatment \[[@pone.0145776.ref049]\].

By comparison, a recent meta-analysis of viscosupplementation for knee OA concluded that local AEs in the injected knee were infrequent; in large RCTs with blinded outcome assessment, 12 of 3,631 patients (0.3%) had a local AE \[[@pone.0145776.ref050]\]. This study was weakened by the fact that it included many patients from unpublished studies and such data must be considered unverifiable \[[@pone.0145776.ref051]\]. A more recent meta-analysis that included 4,866 patients, all from peer-reviewed journal papers, concluded that there were no serious AEs related to HA treatment \[[@pone.0145776.ref051]\]. Thus, HA injection appears to be safe by comparison to TKR \[[@pone.0145776.ref051],[@pone.0145776.ref052]\]. Furthermore, a recent meta-analysis \[[@pone.0145776.ref051]\] concluded that there were large treatment effects 4--26 weeks after HA injection; relative to saline-injected controls, the standardized mean difference following HA injection was an improvement of 0.38--0.43 units for knee pain and of 0.32--0.34 units for knee function (all P \< 0.001).

A potential limitation of this study is that patients who did and did not receive HA injection were not identical at baseline (Tables [1](#pone.0145776.t001){ref-type="table"} and [4](#pone.0145776.t004){ref-type="table"}). Though there were statistically significant differences between HA Users and HA Non-users, the sample size in this database was enormous, so differences that were not clinically meaningful could still be statistically significant. For example, CCI scores were calculated by tallying whether a patient had any of 15 possible comorbid illnesses (*e*.*g*., diabetes, myocardial infarction, congestive heart failure, chronic pulmonary disease, peripheral vascular disease, dementia, cerebrovascular disease, etc.), with a maximum possible score of 15 for patients who had all illnesses \[[@pone.0145776.ref053]\]. HA Users had an average of 0.6 illnesses, while HA Non-users had an average of 0.7 illnesses ([Table 1](#pone.0145776.t001){ref-type="table"}). Data show that 65.5% of HA Users were free of all major disease comorbidities, while 64.4% of HA Non-users were free of all major comorbidities; median number of comorbidities did not differ between HA Users and HA Non-users. A Cox proportional hazards model found no difference in risk of TKR as a function of comorbidity ([Table 2](#pone.0145776.t002){ref-type="table"}). In short, though CCI differences were statistically significant between HA Users and Non-users (p \< 0.0001), we do not believe these differences to be clinically meaningful. Another limitation of this study is that patients who were unwilling to undergo surgery were perhaps more likely to look for alternative treatments such as repeat HA injections; thus [Fig 2](#pone.0145776.g002){ref-type="fig"} could simply reflect a reluctance to undergo surgery. However, we do not think this is a serious limitation; if a patient sought to avoid surgery with HA but the HA treatment failed, then the patient would likely go on to surgery anyway \[[@pone.0145776.ref049]\]. A final weakness of this study is that, if HA injection enabled a patient to avoid TKR entirely, we would not have been sensitive to that outcome. This is because we required TKR to enroll all patients in the database. This could have had the effect of underestimating the efficacy of HA injection. Therefore, we conclude that HA-related delay of TKR is of significant benefit to patients with knee OA.

Conclusions {#sec008}
===========

We present evidence that HA injection is associated with a significant delay in TKR. Patients who received no HA had a median time-to-TKR of \~0.3 years; with one course of HA, the median time to TKR was \>1.0 year (p \< 0.0001); patients who received ≥5 courses delayed TKR by 3.6 years (p \< 0.0001). The dose-response relationship between number of HA courses and time-to-TKR suggests that there is clinical benefit from HAs. This relationship is statistically strong; there is consistency of treatment response between patients; greater use of HA is associated with a longer time-to-TKR; and there is a plausible mechanism linking cause and effect \[[@pone.0145776.ref010]\].
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